Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes

As of June 10th 2020 about 7.2 million individuals have tested positive for, and more than 410,000 have died due to COVID-19. In this review we outline the pathophysiology that underpins the potential use of anti-rheumatic therapies for severe COVID-19 infection and summarize the current evidence re...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Rheumatol Int
Main Authors: Kastritis, Efstathios, Kitas, George D., Vassilopoulos, Dimitrios, Giannopoulos, Georgios, Dimopoulos, Meletios A., Sfikakis, Petros P.
Formato: Artigo
Idioma:Inglês
Publicado: Springer Berlin Heidelberg 2020
Assuntos:
Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7353833/
https://ncbi.nlm.nih.gov/pubmed/32654078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00296-020-04629-x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares